Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics, Biognosys Partner on Proteomics for Biopharma Development

NEW YORK – NeoGenomics announced on Monday that it has entered a global strategic partnership agreement with Swiss proteomics firm Biognosys for biopharmaceutical research and development. 

The agreement will encompass multiple strategic and commercial initiatives, including NeoGenomics' labs offering access to Biognosys proteomics platforms, medical and scientific affairs joint presentations and discussions, and global scientific and technical initiatives, NeoGenomics said in a statement.

Financial and other terms of the deal were not disclosed.

"Partnering with Biognosys gives us the added advantage of expanding into proteomics, data analytics, and subsequent actionable results, not only in early discovery and translational research but ultimately, in clinical trials impacting patient care," Gina Wallar, NeoGenomics' president of pharma services, said in a statement.

The companies have designed a multi-modality approach for protein analysis of tumor samples from late-stage melanoma patients who have been treated with immune checkpoint inhibitors, NeoGenomics said. The collaboration combines Biognosys' TrueDiscovery proteomics platform, which is based on proprietary mass spectrometry technology, with NeoGenomics' proprietary MultiOmyx platform for multiplexed immunofluorescence spatial tissue analysis, the Fort Myers, Florida-based firm added.

Data from the collaboration will be presented at the American Association for Cancer Research this week.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.